切除修复交叉互补基因1和X线修复交叉互补基因1及谷胱甘肽巯基转移酶π 1多态性与晚期胃癌患者生存期的关系

目的 探讨切除修复交叉互补基因1(ERCC1)、X线修复交叉互补基因1(XRCC1)和谷胱甘肽巯基转移酶π1(GSTP1)多态性与中国晚期胃癌患者接受含奥沙利铂方案一线化疗后生存期的关系.方法 85例晚期胃癌患者接受奥沙利铂+5-氟尿嘧啶为基础的联合化疗方案化疗,并在化疗前抽取患者静脉血,提取基因组DNA,以实时荧光定量PCR法行多态性检测,比较不同基因型与患者生存期的关系.结果 85例患者中位至疾病进展时间为5.3个月,中位生存期为8.0个月.ERCC1-118 C/C、XRCC1-399 G/G和GSTP1-105 A/G+G/G基因型为优势基因型,携带3个、2个、1个、0个优势基因型患者的中位生存期分别为12.5、10.0,6.5和4.5个月,组间差异有统计学意义(χ2=35.54,P<0.01).结论 ERCC1-118、XRCC1-399和GSTP1-105基因多态性与中国晚期胃癌患者接受含奥沙利铂化疗方案一线化疗后的生存期相关,可预测患者的预后.

Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy

Objective To evaluate the association between the polymorphisms of excision repair cross complementation group 1 ( ERCC1 ) , X-ray repair cross complementing 1 ( XRCC1) , glutathione S-transferase Pi 1 (GSTP1) and the survival of advanced gastric cancer patients treated with oxaliplatin-based combination chemotherapy. Methods Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. Peripheral venous blood was taken before chemotherapy. DNA was extracted from peripheral venous blood. The genetic polymorphisms were detected by real-time PCR assay. The association between time to progression, overall survival and the polymorphisms was analyzed. Results The median time to progression of the 83 cases was 5.3 months, and the median overall survival was 8.0 months. ERCC1-118 C/C, XRCC1-399 G/G and GSTP1 -105 A/G + G/G were favorable genotypes and the number of the favorable genotypes was associated with survival of the patients. The median overall survival was 12.5 months, 10.0 months, 6.5 months and 4.5 months for patients with 3 favorable genotypes, 2 favorable genotypes, 1 favorable genotype and none favorable genotype, respectively, with a significant difference (χ2 =35. 54, P <0. 01). Conclusion Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.